Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has received approval from the National Medical Products Administration to conduct clinical trials for HLX43 in combination with HLX07 for the treatment of advanced/metastatic solid tumors [1] Group 1: Clinical Trial Approval - The approved clinical trial will focus on the combination of HLX43, a novel DNA topoisomerase I inhibitor, and HLX07, an innovative biological drug targeting EGFR, for treating advanced/metastatic solid tumors [1] - The clinical trials are planned to be conducted in China once conditions are met [1] Group 2: Financial Investment - As of August 2025, the cumulative R&D investment for this treatment plan is approximately RMB 150,000 [1] Group 3: Market Context - There are currently no similar combination therapies approved for market globally [1]